U.S. President Donald Trump’s recent decision to impose 100% tariffs on branded and patented medicines, effective October 1, marks a dramatic turn in the intersection of healthcare and trade policy. By targeting one of the most sensitive aspects of human welfare — access to essential drugs — the U.S. has effectively weaponised healthcare in pursuit of broader economic and political objectives.
Who is Shielded, Who is Exposed?
While the announcement sounds sweeping, it comes with a caveat: imports from the European Union and Japan will continue to face only a 15% tariff. This is significant because these two regions account for nearly three-fourths of all U.S. pharmaceutical imports, including blockbuster medicines such as the Danish-made anti-diabetes and weight-loss drugs Wegovy and Ozempic.
On the other hand, U.K., Switzerland, and Singapore — major pharmaceutical hubs — face the full brunt of the 100% tariff. Their products could become prohibitively expensive, with potential ripple effects across the global drug supply chain.
The Domestic Fallout in the U.S.
American households already spend heavily on prescription drugs, which account for 10% of medical expenses. With tariffs in place, the cost of specialty drugs, cancer therapies, and treatments for rare diseases will escalate sharply. Health insurance companies are expected to transfer much of this burden to policyholders, further straining household budgets.
According to an Ernst & Young study, even a 25% tariff on patented drugs would add $51 billion annually to U.S. healthcare costs. A 100% tariff threatens an even more severe financial shock. Notably, the influential U.S. pharmaceutical lobby, PhRMA, opposed the move, warning that tariffs will “raise costs for patients without addressing structural inefficiencies in the supply chain.”
India’s Narrow Escape — For Now
For India, the world’s leading supplier of low-cost generics, the decision is a temporary reprieve. Generics make up 90% of prescriptions in the U.S., though they account for just 13% of total drug spending. India exported more than $10.5 billion worth of formulations to the U.S. in FY25, underscoring the critical role its pharmaceutical industry plays in American healthcare affordability.
However, the relief may be short-lived. If tariffs are extended to include generics, biosimilars, or Active Pharmaceutical Ingredients (APIs) — a sector where India and China dominate — the consequences for India’s economy could be severe. The uncertainty over APIs is particularly worrying, as they form the backbone of global drug production.
The Bigger Picture: Trade and Geopolitics
The U.S. remains a leading exporter of innovative medicines, and the interaction between tariffs on imports and the competitiveness of U.S. drug exports is yet to be fully understood. What is clear, however, is that the global pharmaceutical supply chain, painstakingly built in the post–World War II liberal order, is now being reshaped under the weight of new political realities.
Protectionism in healthcare trade is especially fraught: unlike steel or electronics, medicines are directly tied to human survival and well-being. By turning healthcare into a trade weapon, the U.S. risks not only inflating domestic drug costs but also destabilising global access to life-saving therapies.
The Way Forward for India
For India, this moment is both a warning and an opportunity. The country’s pharmaceutical industry, long dependent on U.S. demand, must accelerate efforts to diversify export markets and forge alternative trade alliances. Regions such as Africa, Latin America, and Southeast Asia offer growing opportunities for Indian drugmakers.
At the same time, India must invest in API self-reliance and scale up its capacity in biosimilars and innovative research to cushion against future policy shocks.
Conclusion
President Trump’s tariff decision underscores how healthcare is no longer insulated from the global currents of protectionism and geopolitics. For Americans, it promises higher drug bills; for the world, it signals a future where access to essential medicines may increasingly be determined not by medical need, but by political negotiation. For India, it is a wake-up call: the time to reduce overdependence on the U.S. market and prepare for a more fragmented global pharmaceutical order is now.